US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexaria Bioscience Corp

1.35

-0.3400-20.12%

Post-market: 1.34-0.0100-0.74%19:35 EDT

Volume:600.37K

Turnover:797.00K

Market Cap:23.70M

PE:-2.29

High:1.45

Open:1.40

Low:1.23

Close:1.69

Loading ...

Overview Company News Filings

Lexaria Bioscience prices 2M shares at $1.00 in registered direct offering

LEXX: Second Quarter Results

Zacks Small Cap Research

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

ACCESS Newswire

Lexaria Bioscience Corp reports results for the quarter ended February 28 - Earnings Summary

We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully

Simply Wall St.

Lexaria Bioscience Corp expected to post a loss of 15 cents a share - Earnings Preview

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire

Lexaria's Human GLP-1 Study #5 Begins Dosing

ACCESS Newswire

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

ACCESS Newswire

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

ACCESS Newswire

Lexaria receives HREC approval for DehydraTECH-tirzepatide GLP-1 study arm

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

ACCESS Newswire

Lexaria Bioscience granted two new DehydraTECH patents

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

ACCESS Newswire

Lexaria begins biodistribution study for DehydraTECH GLP-1

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

ACCESS Newswire

Lexaria Bioscience provides update on ongoing human study GLP-1-H24-4

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire

Lexaria CEO says FY25 R&D will ‘remain concentrated’ on GLP-1 investigations

Lexaria Releases Annual Letter from the CEO

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LEXX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LEXX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXX\",,,,,undefined,":{"symbol":"LEXX","market":"US","secType":"STK","nameCN":"Lexaria Bioscience Corp","latestPrice":1.35,"timestamp":1745611200000,"preClose":1.69,"halted":0,"volume":600370,"hourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.35,"latestTime":"19:35 EDT","volume":3357,"amount":4492.3827,"timestamp":1745624141809},"delay":0,"floatShares":15696641,"shares":17559179,"eps":-0.588992,"marketStatus":"Not Yet Opened","change":-0.34,"latestTime":"04-25 16:00:00 EDT","open":1.4,"high":1.45,"low":1.23,"amount":796997.899144,"amplitude":0.130178,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.588992,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.69,"preHourTrading":{"tag":"盘前","latestPrice":1.39,"preClose":1.67,"latestTime":"09:23 EDT","volume":66933,"amount":90806.4281745,"timestamp":1745587386251},"postHourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.35,"latestTime":"19:35 EDT","volume":3357,"amount":4492.3827,"timestamp":1745624141809},"volumeRatio":9.120756453170666},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXX\",,,,,undefined,":{"symbol":"LEXX","floatShares":15696641,"roa":"-77.60%","roe":"-145.55%","lyrEps":-0.467971,"volumeRatio":9.120756453170666,"shares":17559179,"dividePrice":0,"high":1.45,"amplitude":0.130178,"preClose":1.69,"low":1.23,"week52Low":1.15,"pbRate":"3.32","psRate":"45.07","week52High":4.44,"institutionHeld":0,"latestPrice":1.35,"eps":-0.588992,"divideRate":0,"volume":600370,"delay":0,"ttmEps":-0.588992,"open":1.4,"prevYearClose":2.1,"prevWeekClose":1.38,"prevMonthClose":1.71,"prevQuarterClose":1.71,"fiveDayClose":1.38,"twentyDayClose":1.75,"sixtyDayClose":1.81},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LEXX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530187333","title":"Lexaria Bioscience prices 2M shares at $1.00 in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2530187333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530187333?lang=en_us&edition=fundamental","pubTime":"2025-04-25 20:15","pubTimestamp":1745583331,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) entered into a definitive agreement with a single institutional investor for the purchase and sale of 2,000,000 shares of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-prices-2m-shares-at-1-00-in-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-prices-2m-shares-at-1-00-in-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LEXX"],"gpt_icon":0},{"id":"2529293935","title":"LEXX: Second Quarter Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2529293935","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529293935?lang=en_us&edition=fundamental","pubTime":"2025-04-24 17:28","pubTimestamp":1745486880,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience Corporation  reported fiscal second quarter 2025 results through the filing of its Form 10-Q. Since our previous update, the company has made progress with its multiple GLP-1 trials, received patent awards in epilepsy and shared its strategy for advancing its development candidates. Lexaria’s GLP-1-H24-4 trial announced that it had enrolled more quickly than expected and that all five study arms completed enrollment. Results for the study are expected before the end of the year. In this report we will bring investors up to date on the status of Lexaria’s various GLP-1 studies and review second quarter financial performance.General and administrative expenses totaled $1.2 million up 118% from $0.6 million due primarily to higher consulting fees and salaries related to the hiring of a new CEO and CFO, increased legal fees due to additional registration statement filings and greater use of legal advisory services. Greater advertising and promotion expenses were incurred","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexx-second-quarter-results-092800220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DHT","BK4007","LEXXW","LEXX","BK4144","MTA","BK4188"],"gpt_icon":0},{"id":"2529868706","title":"Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2529868706","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529868706?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:10","pubTimestamp":1745413800,"startTime":"0","endTime":"0","summary":"Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry. Lexaria's technology could enhance performance and lower side effects. By enhancing the performance of oral dosing choices as a replacement for disliked injections; and by reducing adverse events - often the #1 reason that patients stop using GLP-1 drugs - Lexaria's proprietary DehydraTECH technology could be of vital importance to any of these companies in their pursuit of the next oral GLP-1 drug.Eli Lilly plans to apply for approval to launch the drug for both weight loss and diabetes treatment in 2026 - and that rapid path to market, combined with the fact that it might be only the 2nd oral GLP-1 drug to potentially be approved by the Food and Drug Administration , is likely responsible for the dramatic market response to the news.Although clearly a positive step forward for the weight loss and diabetes treatment sectors, it should still be noted that 13% to 18% of patients receiving the drug ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recent-glp-1-industry-developments-131000677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE000M9KFDE8.USD","BK4533","SG9999003800.SGD","BK4592","LU0289739699.SGD","BK4581","LU0225771236.USD","BK4599","BK4590","LU1057294990.SGD","LEXX","IE00BLSP4452.SGD","LU1894683348.USD","LU0234572021.USD","SG9999013999.USD","BK4568","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","LU0321505439.SGD","BK4007","SGXZ57979304.SGD","LU0321505868.SGD","LU0058720904.USD","IE0002270589.USD","BK4144","LU1883839398.USD","LU0868494617.USD","SG9999002224.SGD","LU0306807586.USD","LU1894683264.USD","LU1066053197.SGD","LU0170899867.USD","SG9999011175.SGD","LU0225284248.USD","IE00B19Z3581.USD","LEXXW","BK4534","LU0122379950.USD","LU0456855351.SGD","GLP","LU0306806265.USD","SG9999001176.SGD","LU0985481810.HKD","BK4585","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4550"],"gpt_icon":1},{"id":"2527142803","title":"Lexaria Bioscience Corp reports results for the quarter ended February 28 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2527142803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527142803?lang=en_us&edition=fundamental","pubTime":"2025-04-15 05:01","pubTimestamp":1744664490,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience Corp reports results for the quarter ended February 28 - Earnings SummaryLexaria Bioscience Corp LEXX.OQ reported a quarterly adjusted loss of 15 cents per share for the quarter end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nL8N3QS1RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX"],"gpt_icon":0},{"id":"2525906187","title":"We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2525906187","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525906187?lang=en_us&edition=fundamental","pubTime":"2025-04-05 20:13","pubTimestamp":1743855237,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So, the natural question for Lexaria Bioscience  shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. Let's start with an examination of the business' cash, relative to its cash burn.Lexaria Bioscience's cash burn of US$6.7m is about 27% of its US$25m market capitalisation. That's fairly no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-lexaria-bioscience-nasdaq-lexx-121357902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","USAW.SI","LU2095319765.USD","IE00BGHQF748.EUR","QLD","TQQQ","IE00B64PRP62.GBP","LEXX","IE00BKPKM429.USD","LEXXW","BK4112","PSQ","NVIW.SI","IE00B3QW5Z07.USD","TSYW.SI","QID","BK4585","USJW.SI","LU2210149790.SGD","NQmain","BK4007","SQQQ","BK4588","LU2210150020.SGD","MNQmain",".IXIC"],"gpt_icon":1},{"id":"2525737523","title":"Lexaria Bioscience Corp  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2525737523","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525737523?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:05","pubTimestamp":1743797106,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience Corp  expected to post a loss of15cents a share - Earnings Preview Lexaria Bioscience Corp LEXX.OQ LEXX.O is expected to report resultson April 7 (estimated) for the period ending F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nL5N3QI1YA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX"],"gpt_icon":0},{"id":"2524487257","title":"Lexaria Updates its Ongoing Human Study GLP-1-H24-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2524487257","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524487257?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:10","pubTimestamp":1743685800,"startTime":"0","endTime":"0","summary":"Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss. KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4  underway in Australia.\"Lexaria is pleased to have reached LPI enrollment completion,\" said John Docherty, President and Chief Scientific Officer of Lexaria Bioscience Corp. \"Dosing is progressing nicely and, at this point, we are expecting the Study to complete on schedule.\". Arm 1 of the Study is utilizing a proprietary, patented DehydraTECH-CBD formulation. Our 2022 diabetes animal study DIAB-A22-1, utilizing DehydraTECH-CBD evidenced weight loss of 7% and reduced blood glucose levels of 19.9%+/-7%  during a multi-week rodent study without the addition of any GLP-1 drugs. Lexaria is looking forward to discovering in humans whether DehydraTECH-CBD studied alone, or together with De","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-updates-ongoing-human-study-131000178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4557","BK4144","LEXXW","GLP","BK4007","ACB","LEXX","BK4590"],"gpt_icon":0},{"id":"2524497651","title":"Lexaria's Human GLP-1 Study #5 Begins Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524497651","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524497651?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:05","pubTimestamp":1743599100,"startTime":"0","endTime":"0","summary":"Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide. KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to announce that dosing has begun as scheduled in its human study GLP-1-H25-5  that is comparing oral DehydraTECH-liraglutide to injected Saxenda-branded liraglutide.On November 20, 2024, Lexaria reported on an earlier 12-week study in rodents which showed that with unlimited food available, oral DehydraTECH-liraglutide demonstrated a 5.88% weight reduction and an 11.54% blood sugar reduction as compared to baseline.The current Study is designed to test pharmacokinetics   and adverse events in humans. Lexaria has previously shown in other GLP-1 PK studies in humans, that certain oral DehydraTECH formulations demonstrated superior bloodstream delivery, as well as reduced adverse events as compared to the oral semaglutide and injectable tirzepati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexarias-human-glp-1-study-130500653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","BK4007","BK4590","GLP","BK4144","LEXX"],"gpt_icon":0},{"id":"2520670605","title":"Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520670605","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520670605?lang=en_us&edition=fundamental","pubTime":"2025-03-18 21:15","pubTimestamp":1742303700,"startTime":"0","endTime":"0","summary":"More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound. As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound. Lexaria's oral capsules worthy of expanded investigation as a viable alternative to injected tirzepatide.Zepbound is currently only available as a once-weekly injection for weight loss. It is not sold by Eli Lilly in any oral format. Lexaria's Study was designed to discover whether the active drug within Zepbound - tirzepatide - could be administered using Lexaria's patented DehydraTECH drug delivery technology via simple oral capsules in order to deliver a useful quantity of tirzepatide into the human bloodstream, as well as provide a viable alternative to disliked injections. The results were unexpectedly positive, showing that orally delivered DehydraTECH-tirzepatide reached roughly","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexarias-dehydratech-tirzepatide-oral-capsules-131500293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2211815571.USD","SG9999015986.USD","LU0114720955.EUR","LU2361044865.SGD","LU0708995401.HKD","SGXZ51526630.SGD","SG9999014914.USD","LU0203202063.USD","LU1720051108.HKD","SGXZ57979304.SGD","LU0385154629.USD","BK4516","LU1983299246.USD","BK4534","LU2023250504.SGD","LU2237443978.SGD","IE00B2B36J28.USD","SG9999015978.USD","SG9999018857.SGD","LU1551013425.SGD","IE0002141913.USD","LEXXW","LU2491049909.HKD","LLY","LU2360106947.USD","LU1061106388.HKD","LU2264538146.SGD","LU2112291526.USD","LU0289739699.SGD","LU0256863902.USD","LU0672654240.SGD","LU1917777945.USD","SG9999018865.SGD","LU0058720904.USD","LU1868837136.USD","BK4588","LU2324357040.USD","SG9999001176.SGD","LU1069344957.HKD","LU0471298694.HKD","BK4599","LU0061475181.USD","SG9999017495.SGD","R","SGXZ31699556.SGD","LU0943347566.SGD","LU0640476718.USD","LU1280957306.USD","LEXX","LU1035775433.USD"],"gpt_icon":1},{"id":"2514804509","title":"The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2514804509","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514804509?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:00","pubTimestamp":1740661200,"startTime":"0","endTime":"0","summary":"Lexaria executing a triple-pronged strategy in obesity and diabetes. Semaglutide recently approved to treat chronic kidney disease. The GLP-1 industry is experiencing revolutionary advancements across multiple healthcare sectors. If there has ever been a class of drugs that could change the world - or is perhaps already changing the world - it would be GLP-1. As tens of millions of people around the world utilize these drugs in their pursuit of better health outcomes, there will of course be unwanted side effects and even negative health outcomes in some fraction of GLP-1 drug users. With that said, the benefits of these drugs overwhelmingly outweigh all of the currently known negative outcomes.As we noted on November 26, 2024, GLP-1 drugs are either approved for use, or are being investigated for use, in all of the following healthcare sectors:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/global-revolution-healthcare-driven-glp-130000643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","BK4137","HCSG","LEXXW","LEXX","BK4590","BK4007","BK4144"],"gpt_icon":0},{"id":"2513722870","title":"Lexaria receives HREC approval for DehydraTECH-tirzepatide GLP-1 study arm","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722870","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513722870?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:15","pubTimestamp":1740406508,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) received lead clinical site human research ethics committee approval that was required before dosing can begin in the 5th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-receives-hrec-approval-for-dehydratech-tirzepatide-glp-1-study-arm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-receives-hrec-approval-for-dehydratech-tirzepatide-glp-1-study-arm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4590","LEXX","BK4144","BK4007","GLP"],"gpt_icon":0},{"id":"2513972986","title":"Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm","url":"https://stock-news.laohu8.com/highlight/detail?id=2513972986","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513972986?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"5th study arm in 12-week Phase 1b Study receives lead clinical site approval. KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee  approval that was required before dosing can begin in the 5th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4,  in Australia.This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms of the Study. The Company is pleased to have received all of the necessary lead clinical site approvals so quickly. Additional HREC approval is still pending for the other clinical sites, which is expected soon.The Study is progressing with both patient recruitment and dosing. The milestone of First Patient First Dose occurred in December 2024 as planned. As a reminder, the 5 Study arms are as follows:. This press release","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ethics-board-approval-received-dehydratech-130000223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","BK4590","ARM","GLP","BK4557","ACB","BK4007","LEXXW","LEXX"],"gpt_icon":0},{"id":"2510387598","title":"Lexaria Bioscience granted two new DehydraTECH patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2510387598","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510387598?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:30","pubTimestamp":1739284246,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) has been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH enhanced p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-granted-two-new-dehydratech-patents?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-granted-two-new-dehydratech-patents?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LEXX","BK4007"],"gpt_icon":0},{"id":"2510385490","title":"Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2510385490","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510385490?lang=en_us&edition=fundamental","pubTime":"2025-02-11 21:00","pubTimestamp":1739278800,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESS Newswire / February 11, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH enhanced processing technology related to the treatment of epilepsy.\"We are thrilled to have received broadened claims related to our proprietary DehydraTECH technology for the treatment of epilepsy,\" said Rich Christopher, CEO of Lexaria. \"Each of our patent awards enhances our ability to reach commercial criticality while providing enhanced value to our potential pharmaceutical partners and, ultimately, to patients.\". Lexaria has received its 5th and 6th US patents granted in its patent family #24, Compositions and Methods for Treating Epilepsy. These patents complement earlier research which indicated that DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-granted-two-dehydratech-patents-130000319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXX","LEXXW"],"gpt_icon":0},{"id":"2509708142","title":"Lexaria begins biodistribution study for DehydraTECH GLP-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2509708142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509708142?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:51","pubTimestamp":1738853497,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-begins-biodistribution-study-for-dehydratech-glp-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-begins-biodistribution-study-for-dehydratech-glp-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4144","BK4590","GLP","BK4007","LEXX"],"gpt_icon":0},{"id":"2509771692","title":"Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2509771692","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509771692?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:40","pubTimestamp":1738852800,"startTime":"0","endTime":"0","summary":"World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules. KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide  rodent biodistribution study .Distribution of a drug once it enters the body can provide vital clues as to the understanding of that drug's ability to bind with targeted receptor cells, avoid concentration at physical sites that might be prone to fostering adverse side effects, and increase the drug's ultimate efficacy. Lexaria hopes to discover whether the DehydraTECH processing of semaglutide improves its biodistribution in any significant way compared to the conventional orally administered semaglutide formulation practice.DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients  enter the bloodstream ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-biodistribution-study-dehydratech-glp-144000532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","LEXXW","LEXX","BK4590","BK4144"],"gpt_icon":0},{"id":"2509284622","title":"Lexaria Bioscience provides update on ongoing human study GLP-1-H24-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2509284622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509284622?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:15","pubTimestamp":1738764956,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has completed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-provides-update-on-ongoing-human-study-glp-1-h24-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-provides-update-on-ongoing-human-study-glp-1-h24-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4144","LEXX","GLP","BK4007","BK4590"],"gpt_icon":0},{"id":"2509810452","title":"Lexaria Updates its Ongoing Human Study GLP-1-H24-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2509810452","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509810452?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:10","pubTimestamp":1738764600,"startTime":"0","endTime":"0","summary":"Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss. KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to provide progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4  underway in Australia.Lexaria has completed its submission to the human research ethics committee  for its planned addition of Study Arm 5 to evaluate performance of its DehydraTECH-tirzepatide formulation, pursuant to the positive findings it previously achieved and released for Human Pilot Study #3 .Arms 2 and 3 of the Study are using DehydraTECH-processed pure semaglutide and will be compared to Study Arm 4 which will use Rybelsus tablets  that contains Novo Nordisk's proprietary salcoprozate sodium","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-updates-ongoing-human-study-141000535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4543","IE00BMPRXN33.USD","BK4585","IE00BMPRXQ63.HKD","ACB","IE00BMPRXR70.SGD","LU0348723411.USD","LEXX","BK4144","BK4141","BK4557","LEXXW","BK4007","BK4590","GLP","BK4588"],"gpt_icon":1},{"id":"2507525629","title":"Lexaria CEO says FY25 R&D will ‘remain concentrated’ on GLP-1 investigations","url":"https://stock-news.laohu8.com/highlight/detail?id=2507525629","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507525629?lang=en_us&edition=fundamental","pubTime":"2025-01-30 22:25","pubTimestamp":1738247154,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) provided an annual letter from CEO Richard Christopher, which read in part, “In 2024, Lexaria made the course changing co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-ceo-says-fy25-rd-will-remain-concentrated-on-glp-1-investigations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-ceo-says-fy25-rd-will-remain-concentrated-on-glp-1-investigations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4590","BK4007","BK4144","GLP","LEXX"],"gpt_icon":0},{"id":"2507215886","title":"Lexaria Releases Annual Letter from the CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507215886","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507215886?lang=en_us&edition=fundamental","pubTime":"2025-01-30 22:15","pubTimestamp":1738246500,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , , a global innovator in drug delivery platforms is pleased to provide this annual letter from its Chief Executive Officer  Richard Christopher as a strategic update to all stakeholders.In 2024, Lexaria made the course changing commitment to becoming an oral based drug delivery enabling technology company focused on one of the largest and fastest growing drug sectors in the world today - GLP-1. To that end, we conducted a series of human and animal studies which produced extremely encouraging pharmacokinetic, weight, blood glucose, insulin, and safety results. The success of these studies is a true testament to the effectiveness, versatility, and promise of our proprietary DehydraTECHTM technology platform within, and outside of, GLP-1.2024 R&D ResultsIn 2024, Lexaria spent virtually all of its time and efforts on conducting a series of human and animal studies which utilized our DehydraTECH technology with th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-releases-annual-letter-ceo-141500696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXX","BK4588","BK4585","XBI","BK4557","ACB","BK4007","LEXXW","BK4581"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LEXX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-14","symbol":"LEXX","fiscalQuarterEnding":"2025/02","expectedEps":-0.16,"name":null,"time":"","type":"earning","dateTimestamp":1744603200000,"reportTimeType":"","actualEps":-0.15},{"market":"US","date":"2025-01-10","symbol":"LEXX","fiscalQuarterEnding":"2024/11","expectedEps":-0.12,"name":null,"time":"","type":"earning","dateTimestamp":1736485200000,"reportTimeType":"","actualEps":-0.16},{"market":"US","date":"2024-11-26","symbol":"LEXX","fiscalQuarterEnding":"2024/08","expectedEps":-0.11,"name":null,"time":"","type":"earning","dateTimestamp":1732597200000,"reportTimeType":"","actualEps":-0.15},{"market":"US","date":"2024-07-12","symbol":"LEXX","fiscalQuarterEnding":"2024/05","expectedEps":-0.09,"name":null,"time":"","type":"earning","dateTimestamp":1720756800000,"reportTimeType":"","actualEps":-0.13},{"market":"US","date":"2024-04-09","symbol":"LEXX","fiscalQuarterEnding":"2024/02","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1712635200000,"reportTimeType":"post","actualEps":-0.06}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LEXX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LEXX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1720670400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LEXX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LEXX","date":"2025-04-25","current":-3.162503,"percent":0.632353,"low":-15.58291,"twenty":-8.674369,"median":-4.921084,"eighty":-2.120821,"high":-0.671866,"avg":-5.449773,"sd":3.498115,"marketCap":29675012},"quantilePoints":[{"date":"2020-05-01","current":-5.561251,"twenty":-33.125317,"median":-14.47305,"eighty":-9.432656,"marketCap":22844005},{"date":"2020-05-08","current":-6.179172,"twenty":-32.823087,"median":-14.344381,"eighty":-9.374504,"marketCap":25382246},{"date":"2020-05-15","current":-6.01942,"twenty":-32.672527,"median":-14.287498,"eighty":-9.273795,"marketCap":24726033},{"date":"2020-05-22","current":-7.153514,"twenty":-32.415471,"median":-14.252578,"eighty":-9.187013,"marketCap":29384559},{"date":"2020-05-29","current":-6.4338,"twenty":-32.157144,"median":-14.181035,"eighty":-9.072999,"marketCap":26428185},{"date":"2020-06-05","current":-6.324753,"twenty":-31.804453,"median":-13.944684,"eighty":-8.999523,"marketCap":25980250},{"date":"2020-06-12","current":-6.148096,"twenty":-31.465594,"median":-13.914538,"eighty":-8.923481,"marketCap":25254596},{"date":"2020-06-19","current":-6.324753,"twenty":-30.601154,"median":-13.785281,"eighty":-8.848785,"marketCap":25980250},{"date":"2020-06-26","current":-6.416353,"twenty":-30.314716,"median":-13.710418,"eighty":-8.718288,"marketCap":26356516},{"date":"2020-07-02","current":-6.302912,"twenty":-30.266598,"median":-13.635945,"eighty":-8.622031,"marketCap":26387871},{"date":"2020-07-10","current":-5.274717,"twenty":-30.090965,"median":-13.515269,"eighty":-8.509786,"marketCap":22083213},{"date":"2020-07-17","current":-6.668826,"twenty":-29.924956,"median":-13.437166,"eighty":-8.299061,"marketCap":27919812},{"date":"2020-07-24","current":-8.152808,"twenty":-29.075663,"median":-13.385222,"eighty":-8.158998,"marketCap":34132676},{"date":"2020-07-31","current":-8.470574,"twenty":-28.457121,"median":-13.361425,"eighty":-8.220324,"marketCap":35463042},{"date":"2020-08-07","current":-8.603064,"twenty":-26.842905,"median":-13.278159,"eighty":-8.246704,"marketCap":36017724},{"date":"2020-08-14","current":-7.957834,"twenty":-26.102655,"median":-13.200237,"eighty":-8.10478,"marketCap":33316394},{"date":"2020-08-21","current":-6.828681,"twenty":-25.613742,"median":-13.084334,"eighty":-8.025356,"marketCap":28589066},{"date":"2020-08-28","current":-6.909335,"twenty":-25.514175,"median":-13.02723,"eighty":-7.895161,"marketCap":28926732},{"date":"2020-09-04","current":-6.29099,"twenty":-25.31504,"median":-12.988635,"eighty":-7.861968,"marketCap":26337958},{"date":"2020-09-11","current":-5.936114,"twenty":-25.19058,"median":-12.942394,"eighty":-7.794164,"marketCap":24852228},{"date":"2020-09-18","current":-5.699529,"twenty":-25.140796,"median":-12.909408,"eighty":-7.730024,"marketCap":23861739},{"date":"2020-09-25","current":-5.591991,"twenty":-24.991445,"median":-12.877303,"eighty":-7.596477,"marketCap":23411518},{"date":"2020-10-02","current":-5.376914,"twenty":-24.853088,"median":-12.809344,"eighty":-7.462976,"marketCap":22511076},{"date":"2020-10-09","current":-5.582312,"twenty":-24.827228,"median":-12.803082,"eighty":-7.350391,"marketCap":23370998},{"date":"2020-10-16","current":-4.577753,"twenty":-24.791342,"median":-12.753628,"eighty":-7.296625,"marketCap":18008862},{"date":"2020-10-23","current":-4.509086,"twenty":-24.692743,"median":-12.710306,"eighty":-7.191411,"marketCap":17738726},{"date":"2020-10-30","current":-4.102811,"twenty":-24.642959,"median":-12.617531,"eighty":-7.089341,"marketCap":16140441},{"date":"2020-11-06","current":-4.495353,"twenty":-24.60819,"median":-12.591652,"eighty":-6.928477,"marketCap":17684699},{"date":"2020-11-13","current":-4.941684,"twenty":-24.545104,"median":-12.477953,"eighty":-6.871324,"marketCap":19440565},{"date":"2020-11-20","current":-4.701352,"twenty":-24.467575,"median":-12.383388,"eighty":-6.668245,"marketCap":18495100},{"date":"2020-11-27","current":-4.250443,"twenty":-24.417791,"median":-12.383388,"eighty":-6.586708,"marketCap":16721226},{"date":"2020-12-04","current":-6.351632,"twenty":-24.344256,"median":-12.358407,"eighty":-6.542848,"marketCap":24987295},{"date":"2020-12-11","current":-6.500409,"twenty":-24.269581,"median":-12.208151,"eighty":-6.513218,"marketCap":25572582},{"date":"2020-12-18","current":-5.893856,"twenty":-24.250423,"median":-12.111807,"eighty":-6.490324,"marketCap":23186407},{"date":"2020-12-24","current":-6.476376,"twenty":-24.206373,"median":-12.096594,"eighty":-6.469175,"marketCap":25478036},{"date":"2020-12-31","current":-5.706169,"twenty":-24.145121,"median":-12.073372,"eighty":-6.440343,"marketCap":22448045},{"date":"2021-01-08","current":-5.76339,"twenty":-24.082892,"median":-12.032914,"eighty":-6.408854,"marketCap":22673155},{"date":"2021-01-15","current":-6.279787,"twenty":-24.020662,"median":-11.942094,"eighty":-6.363076,"marketCap":23377840},{"date":"2021-01-22","current":-5.841025,"twenty":-24.020662,"median":-11.897503,"eighty":-6.324753,"marketCap":21744454},{"date":"2021-01-29","current":-6.348344,"twenty":-23.987708,"median":-11.799266,"eighty":-6.315751,"marketCap":23633057},{"date":"2021-02-05","current":-9.872155,"twenty":-23.906804,"median":-11.730236,"eighty":-6.323595,"marketCap":36751190},{"date":"2021-02-12","current":-9.556795,"twenty":-23.795122,"median":-11.682441,"eighty":-6.324753,"marketCap":35577194},{"date":"2021-02-19","current":-9.460815,"twenty":-23.771743,"median":-11.640151,"eighty":-6.324753,"marketCap":35219890},{"date":"2021-02-26","current":-8.199373,"twenty":-23.771743,"median":-11.551652,"eighty":-6.338908,"marketCap":30523905},{"date":"2021-03-05","current":-7.472673,"twenty":-23.697068,"median":-11.526163,"eighty":-6.350317,"marketCap":27818609},{"date":"2021-03-12","current":-8.720404,"twenty":-23.572608,"median":-11.512737,"eighty":-6.355133,"marketCap":32463551},{"date":"2021-03-19","current":-8.281641,"twenty":-23.448149,"median":-11.410887,"eighty":-6.360832,"marketCap":30830165},{"date":"2021-03-26","current":-7.362982,"twenty":-23.311037,"median":-11.367864,"eighty":-6.363763,"marketCap":27410262},{"date":"2021-04-01","current":-7.664631,"twenty":-23.161686,"median":-11.265208,"eighty":-6.368341,"marketCap":28533215},{"date":"2021-04-09","current":-7.513807,"twenty":-22.975203,"median":-11.171334,"eighty":-6.375521,"marketCap":27971739},{"date":"2021-04-16","current":-10.69035,"twenty":-22.893692,"median":-11.040265,"eighty":-6.389754,"marketCap":25317486},{"date":"2021-04-23","current":-11.487816,"twenty":-22.828043,"median":-11.033138,"eighty":-6.411854,"marketCap":27206089},{"date":"2021-04-30","current":-10.905881,"twenty":-22.707615,"median":-11.034169,"eighty":-6.417931,"marketCap":25827919},{"date":"2021-05-07","current":-13.492257,"twenty":-22.552041,"median":-11.047392,"eighty":-6.425699,"marketCap":31953118},{"date":"2021-05-14","current":-13.341385,"twenty":-22.400201,"median":-11.099089,"eighty":-6.436417,"marketCap":31595815},{"date":"2021-05-21","current":-12.500813,"twenty":-22.351461,"median":-11.172121,"eighty":-6.446058,"marketCap":29605125},{"date":"2021-05-28","current":-13.1043,"twenty":-22.231879,"median":-11.265208,"eighty":-6.458512,"marketCap":31034338},{"date":"2021-06-04","current":-14.89321,"twenty":-22.149928,"median":-11.367864,"eighty":-6.465205,"marketCap":35270934},{"date":"2021-06-11","current":-14.117297,"twenty":-22.118803,"median":-11.410887,"eighty":-6.469175,"marketCap":33433374},{"date":"2021-06-18","current":-14.634572,"twenty":-22.031695,"median":-11.455486,"eighty":-6.472151,"marketCap":34658414},{"date":"2021-06-25","current":-15.087188,"twenty":-21.904299,"median":-11.502925,"eighty":-6.477978,"marketCap":35730324},{"date":"2021-07-02","current":-14.806997,"twenty":-21.780393,"median":-11.526163,"eighty":-6.487355,"marketCap":35066760},{"date":"2021-07-09","current":-15.58291,"twenty":-21.780393,"median":-11.527325,"eighty":-6.499229,"marketCap":36904320},{"date":"2021-07-16","current":-9.056977,"twenty":-21.678409,"median":-11.528487,"eighty":-6.499229,"marketCap":33280244},{"date":"2021-07-23","current":-9.404254,"twenty":-21.573706,"median":-11.526163,"eighty":-6.500409,"marketCap":34556327},{"date":"2021-07-30","current":-9.637817,"twenty":-21.453183,"median":-11.522549,"eighty":-6.505772,"marketCap":35414565},{"date":"2021-08-06","current":-9.560467,"twenty":-21.332659,"median":-11.488954,"eighty":-6.51288,"marketCap":35130339},{"date":"2021-08-13","current":-8.523977,"twenty":-21.212135,"median":-11.423157,"eighty":-6.524386,"marketCap":31321710},{"date":"2021-08-20","current":-8.988077,"twenty":-21.193975,"median":-11.406136,"eighty":-6.528671,"marketCap":33027067},{"date":"2021-08-27","current":-9.421237,"twenty":-21.072867,"median":-11.284971,"eighty":-6.542848,"marketCap":34618732},{"date":"2021-09-03","current":-9.746108,"twenty":-20.982035,"median":-11.189873,"eighty":-6.542848,"marketCap":35812482},{"date":"2021-09-10","current":-9.544997,"twenty":-20.824181,"median":-11.135597,"eighty":-6.542848,"marketCap":35073494},{"date":"2021-09-17","current":-9.777048,"twenty":-20.724576,"median":-11.078307,"eighty":-6.542848,"marketCap":35926172},{"date":"2021-09-24","current":-10.612428,"twenty":-20.701837,"median":-11.034169,"eighty":-6.558291,"marketCap":38995814},{"date":"2021-10-01","current":-9.869868,"twenty":-20.531178,"median":-10.981495,"eighty":-6.611265,"marketCap":36267243},{"date":"2021-10-08","current":-10.179268,"twenty":-20.488995,"median":-10.949822,"eighty":-6.633734,"marketCap":37404148},{"date":"2021-10-15","current":-10.581488,"twenty":-20.488995,"median":-10.905881,"eighty":-6.655994,"marketCap":38882123},{"date":"2021-10-22","current":-10.194738,"twenty":-20.471658,"median":-10.86231,"eighty":-6.666084,"marketCap":37460993},{"date":"2021-10-29","current":-9.575937,"twenty":-20.436451,"median":-10.830411,"eighty":-6.668536,"marketCap":35187184},{"date":"2021-11-05","current":-9.715167,"twenty":-20.327206,"median":-10.804878,"eighty":-6.791676,"marketCap":35698791},{"date":"2021-11-12","current":-10.148328,"twenty":-20.143564,"median":-10.737922,"eighty":-6.827422,"marketCap":37290457},{"date":"2021-11-19","current":-8.616797,"twenty":-20.02632,"median":-10.690687,"eighty":-6.849445,"marketCap":31662781},{"date":"2021-11-26","current":-8.260987,"twenty":-20.0069,"median":-10.671553,"eighty":-6.863479,"marketCap":30355342},{"date":"2021-12-03","current":-6.840174,"twenty":-19.934586,"median":-10.612428,"eighty":-6.863479,"marketCap":27545422},{"date":"2021-12-10","current":-7.025044,"twenty":-19.741749,"median":-10.596796,"eighty":-6.863479,"marketCap":28289893},{"date":"2021-12-17","current":-6.531754,"twenty":-19.615799,"median":-10.578981,"eighty":-6.826164,"marketCap":26303411},{"date":"2021-12-23","current":-6.191866,"twenty":-19.51938,"median":-10.535078,"eighty":-6.679019,"marketCap":24934681},{"date":"2021-12-31","current":-5.955422,"twenty":-19.356074,"median":-10.473198,"eighty":-6.628639,"marketCap":23982521},{"date":"2022-01-07","current":-6.443087,"twenty":-19.236954,"median":-10.457728,"eighty":-6.542848,"marketCap":25946351},{"date":"2022-01-14","current":-5.152781,"twenty":-19.117133,"median":-10.426788,"eighty":-6.542848,"marketCap":27434100},{"date":"2022-01-21","current":-5.052184,"twenty":-18.967952,"median":-10.401429,"eighty":-6.525243,"marketCap":26898510},{"date":"2022-01-28","current":-4.560379,"twenty":-18.668908,"median":-10.364908,"eighty":-6.502913,"marketCap":24280071},{"date":"2022-02-04","current":-4.392718,"twenty":-18.668908,"median":-10.347469,"eighty":-6.489782,"marketCap":23387422},{"date":"2022-02-11","current":-4.007097,"twenty":-18.667483,"median":-10.341251,"eighty":-6.469175,"marketCap":21334327},{"date":"2022-02-18","current":-4.314476,"twenty":-18.617444,"median":-10.333079,"eighty":-6.440892,"marketCap":22970852},{"date":"2022-02-25","current":-3.889735,"twenty":-18.440095,"median":-10.297161,"eighty":-6.416353,"marketCap":20709473},{"date":"2022-03-04","current":-3.710896,"twenty":-18.35776,"median":-10.259288,"eighty":-6.37702,"marketCap":19757313},{"date":"2022-03-11","current":-3.744429,"twenty":-18.272902,"median":-10.22525,"eighty":-6.357467,"marketCap":19935843},{"date":"2022-03-18","current":-3.107317,"twenty":-18.171071,"median":-10.224763,"eighty":-6.324865,"marketCap":16543774},{"date":"2022-03-25","current":-3.845025,"twenty":-17.891037,"median":-10.197982,"eighty":-6.318961,"marketCap":20471433},{"date":"2022-04-01","current":-3.688542,"twenty":-17.881648,"median":-10.179268,"eighty":-6.279787,"marketCap":19638293},{"date":"2022-04-08","current":-3.39234,"twenty":-17.785381,"median":-10.153858,"eighty":-6.221421,"marketCap":18061278},{"date":"2022-04-14","current":-3.185945,"twenty":-17.768281,"median":-10.122944,"eighty":-6.204693,"marketCap":22792322},{"date":"2022-04-22","current":-2.495518,"twenty":-17.575778,"median":-10.086448,"eighty":-6.185731,"marketCap":17852994},{"date":"2022-04-29","current":-2.312514,"twenty":-17.497699,"median":-10.042063,"eighty":-6.147983,"marketCap":16543774},{"date":"2022-05-06","current":-2.370742,"twenty":-17.489943,"median":-9.984656,"eighty":-6.122035,"marketCap":16960344},{"date":"2022-05-13","current":-1.705271,"twenty":-17.39456,"median":-9.962688,"eighty":-6.105634,"marketCap":12199545},{"date":"2022-05-20","current":-1.671997,"twenty":-17.285936,"median":-9.940712,"eighty":-6.09087,"marketCap":11961505},{"date":"2022-05-27","current":-1.713589,"twenty":-17.264742,"median":-9.93387,"eighty":-6.058044,"marketCap":12259055},{"date":"2022-06-03","current":-1.81341,"twenty":-17.257904,"median":-9.920751,"eighty":-6.023867,"marketCap":12973175},{"date":"2022-06-10","current":-1.988096,"twenty":-17.136229,"median":-9.900808,"eighty":-6.017376,"marketCap":14222885},{"date":"2022-06-17","current":-1.938186,"twenty":-17.051331,"median":-9.885602,"eighty":-5.98861,"marketCap":13865825},{"date":"2022-06-24","current":-2.736752,"twenty":-17.004275,"median":-9.878747,"eighty":-5.959552,"marketCap":19578783},{"date":"2022-07-01","current":-2.295877,"twenty":-16.835329,"median":-9.865791,"eighty":-5.937004,"marketCap":16424754},{"date":"2022-07-08","current":-2.428971,"twenty":-16.675346,"median":-9.823458,"eighty":-5.903478,"marketCap":17376914},{"date":"2022-07-15","current":-2.438392,"twenty":-16.66574,"median":-9.800253,"eighty":-5.868301,"marketCap":17019854},{"date":"2022-07-22","current":-2.387237,"twenty":-16.651735,"median":-9.761578,"eighty":-5.823139,"marketCap":16662794},{"date":"2022-07-29","current":-2.301978,"twenty":-16.589073,"median":-9.747431,"eighty":-5.807068,"marketCap":16067694},{"date":"2022-08-05","current":-2.408551,"twenty":-16.505285,"median":-9.746108,"eighty":-5.766272,"marketCap":16811569},{"date":"2022-08-12","current":-2.796477,"twenty":-16.452472,"median":-9.699697,"eighty":-5.752153,"marketCap":19519273},{"date":"2022-08-19","current":-2.361659,"twenty":-16.36772,"median":-9.668758,"eighty":-5.723569,"marketCap":16484264},{"date":"2022-08-26","current":-2.472495,"twenty":-16.30819,"median":-9.653288,"eighty":-5.719391,"marketCap":17257894},{"date":"2022-09-02","current":-2.544965,"twenty":-16.294271,"median":-9.637817,"eighty":-5.698952,"marketCap":17763729},{"date":"2022-09-09","current":-2.702693,"twenty":-16.238593,"median":-9.622347,"eighty":-5.63867,"marketCap":18864663},{"date":"2022-09-16","current":-2.417077,"twenty":-16.234654,"median":-9.606878,"eighty":-5.600553,"marketCap":16871079},{"date":"2022-09-23","current":-2.105884,"twenty":-16.195923,"median":-9.584217,"eighty":-5.561251,"marketCap":14698965},{"date":"2022-09-30","current":-2.088832,"twenty":-16.194972,"median":-9.568073,"eighty":-5.554352,"marketCap":14579945},{"date":"2022-10-07","current":-1.884212,"twenty":-16.117012,"median":-9.560467,"eighty":-5.500415,"marketCap":13151705},{"date":"2022-10-14","current":-1.798953,"twenty":-16.06593,"median":-9.544081,"eighty":-5.437212,"marketCap":12556605},{"date":"2022-10-21","current":-1.756324,"twenty":-16.055261,"median":-9.518871,"eighty":-5.376914,"marketCap":12259055},{"date":"2022-10-28","current":-1.901263,"twenty":-16.055261,"median":-9.506322,"eighty":-5.316693,"marketCap":13270725},{"date":"2022-11-04","current":-1.853092,"twenty":-16.018697,"median":-9.483058,"eighty":-5.249722,"marketCap":12934494},{"date":"2022-11-11","current":-2.012099,"twenty":-15.999369,"median":-9.465212,"eighty":-5.161838,"marketCap":14044355},{"date":"2022-11-18","current":-1.875686,"twenty":-15.953664,"median":-9.433393,"eighty":-5.052184,"marketCap":13092195},{"date":"2022-11-25","current":-2.020625,"twenty":-15.921079,"median":-9.421237,"eighty":-4.916007,"marketCap":14103865},{"date":"2022-12-02","current":-2.414922,"twenty":-15.800117,"median":-9.406458,"eighty":-4.808471,"marketCap":17554849},{"date":"2022-12-09","current":-2.398631,"twenty":-15.771913,"median":-9.374504,"eighty":-4.781462,"marketCap":17436424},{"date":"2022-12-16","current":-2.193969,"twenty":-15.76565,"median":-9.351067,"eighty":-4.644331,"marketCap":15948674},{"date":"2022-12-23","current":-2.005681,"twenty":-15.66997,"median":-9.282007,"eighty":-4.550807,"marketCap":14579945},{"date":"2022-12-30","current":-2.013867,"twenty":-15.646442,"median":-9.280758,"eighty":-4.497998,"marketCap":14639455},{"date":"2023-01-06","current":-2.202156,"twenty":-15.566057,"median":-9.2003,"eighty":-4.46149,"marketCap":16008184},{"date":"2023-01-13","current":-2.267647,"twenty":-15.371731,"median":-9.154215,"eighty":-4.348865,"marketCap":16484264},{"date":"2023-01-20","current":-2.301829,"twenty":-15.296539,"median":-9.072941,"eighty":-4.332713,"marketCap":16186714},{"date":"2023-01-27","current":-2.488006,"twenty":-15.134452,"median":-8.999523,"eighty":-4.281096,"marketCap":17495934},{"date":"2023-02-03","current":-2.547244,"twenty":-15.061324,"median":-8.939785,"eighty":-4.234421,"marketCap":17912503},{"date":"2023-02-10","current":-2.377992,"twenty":-14.980795,"median":-8.912362,"eighty":-4.200782,"marketCap":16722304},{"date":"2023-02-17","current":-2.572378,"twenty":-14.909476,"median":-8.88494,"eighty":-4.07975,"marketCap":18089248},{"date":"2023-02-24","current":-2.538782,"twenty":-14.844896,"median":-8.819202,"eighty":-4.017157,"marketCap":17852994},{"date":"2023-03-03","current":-2.648795,"twenty":-14.786699,"median":-8.718288,"eighty":-3.831612,"marketCap":18626623},{"date":"2023-03-10","current":-2.488006,"twenty":-14.7336,"median":-8.624543,"eighty":-3.777961,"marketCap":17495934},{"date":"2023-03-17","current":-2.157964,"twenty":-14.643442,"median":-8.603064,"eighty":-3.688542,"marketCap":15175044},{"date":"2023-03-24","current":-2.127971,"twenty":-14.519701,"median":-8.554917,"eighty":-3.567825,"marketCap":14964125},{"date":"2023-03-31","current":-2.315232,"twenty":-14.463957,"median":-8.486299,"eighty":-3.391222,"marketCap":16280968},{"date":"2023-04-06","current":-1.979013,"twenty":-14.378658,"median":-8.403234,"eighty":-3.335336,"marketCap":13916636},{"date":"2023-04-14","current":-1.966245,"twenty":-14.287498,"median":-8.311435,"eighty":-3.154494,"marketCap":13826851},{"date":"2023-04-21","current":-1.907234,"twenty":-14.209652,"median":-8.249563,"eighty":-2.791565,"marketCap":13168430},{"date":"2023-04-28","current":-1.892843,"twenty":-14.052638,"median":-8.158239,"eighty":-2.73978,"marketCap":13069068},{"date":"2023-05-05","current":-1.187686,"twenty":-13.914167,"median":-8.083856,"eighty":-2.69968,"marketCap":8200340},{"date":"2023-05-12","current":-0.679495,"twenty":-13.712693,"median":-7.963612,"eighty":-2.682794,"marketCap":4691552},{"date":"2023-05-19","current":-1.035296,"twenty":-13.580704,"median":-7.870301,"eighty":-2.589574,"marketCap":7148163},{"date":"2023-05-26","current":-0.878958,"twenty":-13.460618,"median":-7.865587,"eighty":-2.570177,"marketCap":6068737},{"date":"2023-06-02","current":-0.890678,"twenty":-13.412897,"median":-7.788843,"eighty":-2.562883,"marketCap":6149654},{"date":"2023-06-07","current":-0.891264,"twenty":-13.379485,"median":-7.750301,"eighty":-2.551939,"marketCap":6153699},{"date":"2023-06-15","current":-0.846378,"twenty":-13.234305,"median":-7.6805,"eighty":-2.544965,"marketCap":5843789},{"date":"2023-06-23","current":-0.978573,"twenty":-13.163346,"median":-7.611749,"eighty":-2.520854,"marketCap":6756527},{"date":"2023-06-30","current":-0.870169,"twenty":-13.029994,"median":-7.521467,"eighty":-2.513394,"marketCap":6008050},{"date":"2023-07-07","current":-0.902397,"twenty":-12.943419,"median":-7.472673,"eighty":-2.504275,"marketCap":6230570},{"date":"2023-07-14","current":-0.972714,"twenty":-12.889745,"median":-7.435218,"eighty":-2.488006,"marketCap":6716069},{"date":"2023-07-21","current":-0.892153,"twenty":-12.803082,"median":-7.349407,"eighty":-2.465674,"marketCap":6149654},{"date":"2023-07-28","current":-0.933239,"twenty":-12.729177,"median":-7.31323,"eighty":-2.440772,"marketCap":6432861},{"date":"2023-08-04","current":-0.987238,"twenty":-12.617531,"median":-7.225926,"eighty":-2.428809,"marketCap":6805077},{"date":"2023-08-11","current":-1.197364,"twenty":-12.500813,"median":-7.101059,"eighty":-2.42134,"marketCap":8253483},{"date":"2023-08-18","current":-1.220842,"twenty":-12.383388,"median":-7.064426,"eighty":-2.41243,"marketCap":8415316},{"date":"2023-08-25","current":-1.279536,"twenty":-12.336572,"median":-6.955491,"eighty":-2.398735,"marketCap":8819898},{"date":"2023-09-01","current":-1.232463,"twenty":-12.11462,"median":-6.875913,"eighty":-2.387237,"marketCap":8495423},{"date":"2023-09-08","current":-1.013064,"twenty":-12.086798,"median":-6.828681,"eighty":-2.377992,"marketCap":6983093},{"date":"2023-09-15","current":-1.115428,"twenty":-11.968099,"median":-6.668826,"eighty":-2.370742,"marketCap":7688693},{"date":"2023-09-22","current":-1.079975,"twenty":-11.813295,"median":-6.618092,"eighty":-2.362271,"marketCap":7444318},{"date":"2023-09-29","current":-1.138669,"twenty":-11.717442,"median":-6.542848,"eighty":-2.353044,"marketCap":7848900},{"date":"2023-10-06","current":-1.198664,"twenty":-11.638981,"median":-6.520681,"eighty":-2.340161,"marketCap":8262448},{"date":"2023-10-13","current":-1.276707,"twenty":-11.526163,"median":-6.499819,"eighty":-2.320472,"marketCap":8800396},{"date":"2023-10-20","current":-1.407128,"twenty":-11.488271,"median":-6.473736,"eighty":-2.310478,"marketCap":9699395},{"date":"2023-10-27","current":-1.459244,"twenty":-11.407561,"median":-6.454631,"eighty":-2.307051,"marketCap":10058632},{"date":"2023-11-03","current":-1.863141,"twenty":-11.200524,"median":-6.416353,"eighty":-2.296343,"marketCap":12842718},{"date":"2023-11-10","current":-2.221231,"twenty":-11.072124,"median":-6.374521,"eighty":-2.286817,"marketCap":15311046},{"date":"2023-11-17","current":-1.966568,"twenty":-10.97961,"median":-6.351632,"eighty":-2.246358,"marketCap":13555640},{"date":"2023-11-24","current":-2.019895,"twenty":-10.923124,"median":-6.324753,"eighty":-2.211171,"marketCap":13462399},{"date":"2023-12-01","current":-2.312857,"twenty":-10.83906,"median":-6.280532,"eighty":-2.210358,"marketCap":15414961},{"date":"2023-12-08","current":-2.220343,"twenty":-10.797412,"median":-6.231466,"eighty":-2.210358,"marketCap":14798363},{"date":"2023-12-15","current":-2.143248,"twenty":-10.687142,"median":-6.201269,"eighty":-2.187213,"marketCap":14284530},{"date":"2023-12-22","current":-2.066153,"twenty":-10.612428,"median":-6.179172,"eighty":-2.171698,"marketCap":13770698},{"date":"2023-12-29","current":-1.973638,"twenty":-10.596958,"median":-6.140861,"eighty":-2.157964,"marketCap":13154100},{"date":"2024-01-05","current":-2.143248,"twenty":-10.573585,"median":-6.117977,"eighty":-2.139346,"marketCap":14284530},{"date":"2024-01-12","current":-2.343696,"twenty":-10.462732,"median":-6.097421,"eighty":-2.131306,"marketCap":15620494},{"date":"2024-01-19","current":-2.742435,"twenty":-10.414921,"median":-6.060406,"eighty":-2.131152,"marketCap":16696705},{"date":"2024-01-26","current":-2.530945,"twenty":-10.363099,"median":-6.025016,"eighty":-2.131306,"marketCap":15409096},{"date":"2024-02-02","current":-2.721633,"twenty":-10.341251,"median":-6.014533,"eighty":-2.131306,"marketCap":16570056},{"date":"2024-02-09","current":-3.293696,"twenty":-10.266818,"median":-5.973923,"eighty":-2.131306,"marketCap":20052934},{"date":"2024-02-16","current":-4.091117,"twenty":-10.224822,"median":-5.937004,"eighty":-2.131306,"marketCap":24907855},{"date":"2024-02-23","current":-5.054829,"twenty":-10.196036,"median":-5.895319,"eighty":-2.131306,"marketCap":30775207},{"date":"2024-03-01","current":-7.68245,"twenty":-10.148328,"median":-5.877884,"eighty":-2.131461,"marketCap":46772892},{"date":"2024-03-08","current":-10.165167,"twenty":-10.086448,"median":-5.877884,"eighty":-2.131461,"marketCap":61888365},{"date":"2024-03-15","current":-7.827179,"twenty":-10.040038,"median":-5.877884,"eighty":-2.131461,"marketCap":47654041},{"date":"2024-03-22","current":-6.993635,"twenty":-9.962688,"median":-5.877884,"eighty":-2.131461,"marketCap":42579195},{"date":"2024-03-28","current":-7.542554,"twenty":-9.935991,"median":-5.877884,"eighty":-2.131461,"marketCap":45921166},{"date":"2024-04-05","current":-6.63909,"twenty":-9.90079,"median":-5.861912,"eighty":-2.131306,"marketCap":40420623},{"date":"2024-04-12","current":-5.945755,"twenty":-9.870325,"median":-5.861912,"eighty":-2.131306,"marketCap":32343039},{"date":"2024-04-19","current":-5.32986,"twenty":-9.807988,"median":-5.814067,"eighty":-2.131306,"marketCap":28992764},{"date":"2024-04-26","current":-5.18773,"twenty":-9.748753,"median":-5.782168,"eighty":-2.131461,"marketCap":28219623},{"date":"2024-05-03","current":-7.10648,"twenty":-9.715167,"median":-5.779641,"eighty":-2.131461,"marketCap":38657019},{"date":"2024-05-10","current":-8.527776,"twenty":-9.653288,"median":-5.779641,"eighty":-2.131461,"marketCap":46388422},{"date":"2024-05-17","current":-7.438116,"twenty":-9.622347,"median":-5.779641,"eighty":-2.131461,"marketCap":40461013},{"date":"2024-05-24","current":-6.822221,"twenty":-9.584217,"median":-5.779641,"eighty":-2.131461,"marketCap":37110738},{"date":"2024-05-31","current":-9.451618,"twenty":-9.560467,"median":-5.779641,"eighty":-2.131461,"marketCap":51413835},{"date":"2024-06-07","current":-8.077699,"twenty":-9.529527,"median":-5.779641,"eighty":-2.131461,"marketCap":43940144},{"date":"2024-06-14","current":-8.66286,"twenty":-9.498587,"median":-5.777581,"eighty":-2.131306,"marketCap":47123239},{"date":"2024-06-21","current":-7.583294,"twenty":-9.463548,"median":-5.770513,"eighty":-2.131152,"marketCap":41250738},{"date":"2024-06-28","current":-6.925022,"twenty":-9.421237,"median":-5.76339,"eighty":-2.130688,"marketCap":37669944},{"date":"2024-07-05","current":-6.951353,"twenty":-9.404254,"median":-5.76339,"eighty":-2.130688,"marketCap":37813176},{"date":"2024-07-12","current":-7.398978,"twenty":-9.312947,"median":-5.76339,"eighty":-2.130688,"marketCap":40248116},{"date":"2024-07-15","current":-9.095179,"twenty":-9.282007,"median":-5.76339,"eighty":-2.130688,"marketCap":44110471},{"date":"2024-08-02","current":-12.974484,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":62924615},{"date":"2024-08-09","current":-10.790338,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":52331778},{"date":"2024-08-16","current":-10.26875,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":49802145},{"date":"2024-08-23","current":-9.87756,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":47904921},{"date":"2024-08-30","current":-10.529544,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":51066962},{"date":"2024-09-06","current":-10.757738,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":52173676},{"date":"2024-09-13","current":-11.474921,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":55651921},{"date":"2024-09-20","current":-10.26875,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":49802145},{"date":"2024-09-27","current":-9.681965,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":46956308},{"date":"2024-10-04","current":-10.790338,"twenty":-9.20682,"median":-5.725627,"eighty":-2.124643,"marketCap":52331778},{"date":"2024-10-11","current":-9.975358,"twenty":-9.214735,"median":-5.725627,"eighty":-2.124643,"marketCap":48379227},{"date":"2024-10-18","current":-9.225576,"twenty":-9.216122,"median":-5.725627,"eighty":-2.124643,"marketCap":44742880},{"date":"2024-10-25","current":-9.824086,"twenty":-9.213308,"median":-5.725627,"eighty":-2.124643,"marketCap":47645581},{"date":"2024-10-31","current":-8.168746,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":39617388},{"date":"2024-11-08","current":-8.348674,"twenty":-9.105428,"median":-5.722197,"eighty":-2.123533,"marketCap":40490018},{"date":"2024-11-15","current":-7.628961,"twenty":-9.066105,"median":-5.722197,"eighty":-2.123533,"marketCap":36999499},{"date":"2024-11-22","current":-7.772904,"twenty":-9.020491,"median":-5.722197,"eighty":-2.123533,"marketCap":37697603},{"date":"2024-11-29","current":-6.263889,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":36301395},{"date":"2024-12-06","current":-7.046875,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":40839069},{"date":"2024-12-13","current":-6.805956,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":39442862},{"date":"2024-12-20","current":-6.655382,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":38570232},{"date":"2024-12-27","current":-7.137219,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":41362647},{"date":"2025-01-03","current":-6.926415,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":40140966},{"date":"2025-01-10","current":-6.655382,"twenty":-9.001541,"median":-5.722194,"eighty":-2.122424,"marketCap":38570232},{"date":"2025-01-17","current":-4.736024,"twenty":-8.999523,"median":-5.708343,"eighty":-2.122424,"marketCap":34666373},{"date":"2025-01-24","current":-4.364336,"twenty":-8.988077,"median":-5.687855,"eighty":-2.122424,"marketCap":31945721},{"date":"2025-01-31","current":-4.364336,"twenty":-8.953496,"median":-5.614061,"eighty":-2.122424,"marketCap":31945721},{"date":"2025-02-07","current":-4.532195,"twenty":-8.939785,"median":-5.573822,"eighty":-2.122424,"marketCap":33174402},{"date":"2025-02-14","current":-3.66892,"twenty":-8.895257,"median":-5.554362,"eighty":-2.122424,"marketCap":26855468},{"date":"2025-02-21","current":-3.429121,"twenty":-8.720404,"median":-5.505891,"eighty":-2.122424,"marketCap":25100209},{"date":"2025-02-28","current":-3.716879,"twenty":-8.66286,"median":-5.444257,"eighty":-2.122424,"marketCap":27206520},{"date":"2025-03-07","current":-3.309222,"twenty":-8.674369,"median":-5.376914,"eighty":-2.120821,"marketCap":24222579},{"date":"2025-03-14","current":-3.165343,"twenty":-8.674369,"median":-5.344313,"eighty":-2.120821,"marketCap":23169424},{"date":"2025-03-21","current":-3.788819,"twenty":-8.674369,"median":-5.316693,"eighty":-2.120821,"marketCap":27733098},{"date":"2025-03-28","current":-4.196477,"twenty":-8.674369,"median":-5.211418,"eighty":-2.120821,"marketCap":30717039},{"date":"2025-04-04","current":-3.66892,"twenty":-8.674369,"median":-5.166169,"eighty":-2.120821,"marketCap":26855468},{"date":"2025-04-11","current":-3.213302,"twenty":-8.66286,"median":-5.148914,"eighty":-2.122424,"marketCap":23520475},{"date":"2025-04-17","current":-2.619825,"twenty":-8.66286,"median":-5.027237,"eighty":-2.122424,"marketCap":24582850},{"date":"2025-04-25","current":-3.162503,"twenty":-8.674369,"median":-4.921084,"eighty":-2.120821,"marketCap":29675012}],"updateTime":1745792785041}}}